









Markets
/
Stocks
/
nasdaq-glsi
/

Greenwich Lifesciences Inc

GLSI

29.000USD

+3.810+15.13%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

400.04MMarket Cap

LossP/E TTM



Greenwich Lifesciences Inc

29.000

+3.810+15.13%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Greenwich Lifesciences Inc

Currency: USD Updated: 2026-02-06

Key Insights

Greenwich Lifesciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 114 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 47.50.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Greenwich Lifesciences Inc's Score

Industry at a Glance

Industry Ranking

114 / 392

Overall Ranking

248 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Greenwich Lifesciences Inc Highlights

StrengthsRisks

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. It has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -19.74, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.32M shares, decreasing 27.48% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 624.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.04.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

47.500

Target Price

+88.57%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Greenwich Lifesciences Inc is 6.92, ranking 184 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.92

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.83

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Greenwich Lifesciences Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Greenwich Lifesciences Inc is 6.53, ranking 257 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -19.74, which is -72.93% below the recent high of -5.34 and -73.94% above the recent low of -34.33.

Score

Industry at a Glance

Previous score

6.53

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 114/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Greenwich Lifesciences Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 42.00, with a high of 45.00 and a low of 39.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

47.500

Target Price

+88.57%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Greenwich Lifesciences Inc

GLSI

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Greenwich Lifesciences Inc is 9.16, ranking 34 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 35.40 and the support level at 21.30, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.36

Change

1.8

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-1.169

Neutral

RSI(14)

56.667

Neutral

STOCH(KDJ)(9,3,3)

40.292

Neutral

ATR(14)

4.339

High Vlolatility

CCI(14)

1.439

Neutral

Williams %R

36.170

Buy

TRIX(12,20)

1.713

Sell

StochRSI(14)

44.896

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

28.239

Buy

MA10

29.406

Sell

MA20

27.459

Buy

MA50

19.353

Buy

MA100

14.514

Buy

MA200

12.522

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Greenwich Lifesciences Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 9.53%, representing a quarter-over-quarter decrease of 8.44%. The largest institutional shareholder is The Vanguard, holding a total of 296.62K shares, representing 2.14% of shares outstanding, with 4.11% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Patel (Snehal)

5.60M

+0.20%

McWilliams (David B)

620.33K

Hallock (Kenneth)

397.33K

BlackRock Institutional Trust Company, N.A.

329.40K

-1.25%

Rothe (Eric)

313.25K

The Vanguard Group, Inc.

Star Investors

282.18K

+4.90%

Thompson (Jaye L)

264.14K

+0.38%

Geode Capital Management, L.L.C.

142.12K

+2.25%

Daugherty (Frank Joseph)

90.13K

DIM Funds SICAV S.A.

87.00K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Greenwich Lifesciences Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 1.52. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.